Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$4.76 -2.9%	$5.70	$2.90 ▼ $11.16	$386.07M	0.47	3.34 million shs	6.33 million shs
LLY Eli Lilly and Company	$779.60 +0.0%	$773.61	$677.09 ▼ $972.53	$739.87B	0.4	3.67 million shs	1.45 million shs
NVO Novo Nordisk A/S	$69.05 -1.1%	$69.96	$57.00 ▼ $143.69	$308.84B	0.64	7.26 million shs	4.05 million shs
PFE Pfizer	$25.45 +0.5%	$23.72	$20.92 ▼ $31.54	$144.29B	0.58	41.72 million shs	27.10 million shs
RHHBY Roche	$40.44 -1.7%	$40.11	$33.76 ▼ $44.31	$257.92B	0.45	1.24 million shs	624,514 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	+36.00%	-13.30%	+12.26%	-27.88%
LLY Eli Lilly and Company	0.00%	+0.44%	+1.67%	+5.70%	-13.20%
NVO Novo Nordisk A/S	0.00%	+0.80%	-4.39%	+10.34%	-50.36%
PFE Pfizer	0.00%	+5.16%	+8.65%	+10.68%	-8.04%
RHHBY Roche	0.00%	-1.15%	-0.88%	+7.41%	+18.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.2387 of 5 stars	3.5	1.0	0.0	0.0	2.5	1.7	0.6
LLY Eli Lilly and Company	4.9878 of 5 stars	4.4	4.0	3.3	4.0	3.0	1.7	1.9
NVO Novo Nordisk A/S	4.6349 of 5 stars	4.1	5.0	2.5	0.0	2.9	0.0	2.5
PFE Pfizer	4.9763 of 5 stars	3.2	3.0	4.2	4.5	2.8	1.7	3.1
RHHBY Roche	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	3.00	Buy	$19.00	299.16% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	29.76% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	62.20% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside
RHHBY Roche	2.57	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALT, RHHBY, NVO, PFE, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00
5/1/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	19,304.18	N/A	N/A	$1.74 per share	2.74
LLY Eli Lilly and Company	$45.04B	16.40	$14.22 per share	54.84	$15.03 per share	51.87
NVO Novo Nordisk A/S	$42.12B	7.32	$3.89 per share	17.73	$4.66 per share	14.82
PFE Pfizer	$63.63B	2.27	$4.37 per share	5.82	$15.62 per share	1.63
RHHBY Roche	$68.73B	3.75	$3.30 per share	12.27	$6.44 per share	6.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	63.43	25.05	1.14	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.43	14.82	1.35	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
RHHBY Roche	$9.40B	N/A	0.00	13.48	3.11	N/A	N/A	N/A	7/24/2025 (Estimated)

Latest ALT, RHHBY, NVO, PFE, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.77%	N/A	48.82%	11 Years
NVO Novo Nordisk A/S	$1.64	2.38%	N/A	48.52%	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years
RHHBY Roche	$0.87	2.15%	N/A	N/A	N/A

Latest ALT, RHHBY, NVO, PFE, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
LLY Eli Lilly and Company	2.18	1.37	1.06
NVO Novo Nordisk A/S	0.70	0.74	0.56
PFE Pfizer	0.64	1.26	0.96
RHHBY Roche	0.85	1.48	1.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
RHHBY Roche	103,249	6.38 billion	N/A	Not Optionable

ALT, RHHBY, NVO, PFE, and LLY Headlines

Recent News About These Companies

RHHBY - Roche Holding AG ADR Chart - Morningstar

July 3 at 10:02 PM | morningstar.comM

Changes to the Roche Enlarged Corporate Executive Committee

June 30, 2025 | globenewswire.com

RHHBY - Roche Holding AG ADR Trailing Returns - Morningstar

June 27, 2025 | morningstar.comM

RHHBY Roche Holding AG - Seeking Alpha

June 27, 2025 | seekingalpha.com

RHHBY - Roche Holding AG ADR Key Metrics - Morningstar

June 25, 2025 | morningstar.comM

RHHBY - Roche Holding AG ADR Dividends - Morningstar

June 24, 2025 | morningstar.comM

Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript

June 23, 2025 | seekingalpha.com

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

June 23, 2025 | uk.finance.yahoo.com

Altrius Capital Management Inc Acquires 6,545 Shares of Roche Holding AG (OTCMKTS:RHHBY)

June 22, 2025 | marketbeat.com

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | uk.finance.yahoo.com

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | finance.yahoo.com

Roche's Genentech reports positive results from lymphoma trial

June 20, 2025 | msn.com

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | businesswire.com $https://www.businesswire.com/news/home/20250620976164/en/genentech%e2%80%99s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma/$

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/20/3102847/0/en/roche-s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma.html$

UBS Keeps Their Buy Rating on Roche Holding AG (RHHVF)

June 18, 2025 | theglobeandmail.com

Roche And Prothena: Why Moving On Makes Sense

June 18, 2025 | seekingalpha.com

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 17, 2025 | marketbeat.com

Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue

June 16, 2025 | seekingalpha.com

Sarepta crashes after second death linked to Roche-partnered Elevidys

June 16, 2025 | msn.com

Genentech Provides Update on Phase III Verona Study

June 16, 2025 | businesswire.com

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

June 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
By Jeffrey Neal Johnson | June 13, 2025
View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Why Smart Money Just Bought $1.3B of Altria Stock
By Gabriel Osorio-Mazilli | June 10, 2025
View Why Smart Money Just Bought $1.3B of Altria Stock

ALT, RHHBY, NVO, PFE, and LLY Company Descriptions

Altimmune NASDAQ:ALT

$4.76 -0.14 (-2.86%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$4.76 +0.00 (+0.08%)

As of 07/3/2025 04:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Eli Lilly and Company NYSE:LLY

$779.60 +0.32 (+0.04%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$778.00 -1.60 (-0.20%)

As of 07/3/2025 04:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$69.05 -0.77 (-1.10%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$69.12 +0.08 (+0.11%)

As of 07/3/2025 04:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 07/3/2025 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche OTCMKTS:RHHBY

$40.44 -0.71 (-1.73%)

As of 07/3/2025 01:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALT, RHHBY, NVO, PFE, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALT, RHHBY, NVO, PFE, and LLY Earnings

Compare Dividends

Latest ALT, RHHBY, NVO, PFE, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALT, RHHBY, NVO, PFE, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALT, RHHBY, NVO, PFE, and LLY Company Descriptions

Altimmune NASDAQ:ALT

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

Roche OTCMKTS:RHHBY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools